Clinical Trial Update: Pegcetacoplan Long Term Safety and Efficacy Extension Study [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy extension study for pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: PNH | Phase 3 | Status: COMPLETED